24-Aug-2026 09:02:42

AUROBINDO PHARMA: US FDA INSPECTION CONCLUDED AT SUBSIDIARY

• Lannett Company LLC, a wholly owned step-down subsidiary, underwent routine inspection by the US FDA from August 17-21, 2026. • The inspection concluded with four observations, which are procedural in nature. • The company will respond to the US FDA within the stipulated timeline. • Aurobindo Pharma is committed to maintaining robust quality and compliance standards. Impact: Neutral (Routine procedural inspection with procedural observations, no immediate negative impact stated.)

Aurobindo Pharma Limited

← Back to feed